Form 4: KalVista Pharmaceuticals CEO Acquires Shares Through PSU Vesting, Sells Portion for Tax Obligations

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, acquired 87,500 shares of common stock through the vesting of performance stock units due to achieved performance metrics, subsequently selling 32,979 shares to cover tax withholding obligations.

Summary

• Benjamin L. Palleiko, CEO and Director of KalVista Pharmaceuticals, Inc., reported changes in his beneficial ownership.
• On July 8, 2025, Palleiko acquired 87,500 shares of KalVista Common Stock. These shares were earned upon the 100% vesting of performance stock units (PSUs) granted on January 11, 2023, as the Issuer achieved its performance data metric goals.
• Following this acquisition, Palleiko's direct beneficial ownership increased to 402,574 shares.
• On July 9, 2025, Palleiko disposed of 32,979 shares of Common Stock at a price of $15.6925 per share.
• This sale was a "sell to cover" transaction specifically to satisfy tax withholding obligations related to the vesting and settlement of the PSUs and was not a discretionary transaction.
• After these transactions, Palleiko's direct beneficial ownership stands at 369,595 shares.

Sentiment

Score: 7

Explanation: The vesting of performance-based equity indicates successful achievement of company performance metrics, which is positive. The subsequent sale is non-discretionary and for tax purposes, so it does not reflect negative sentiment from the insider.

Positives

• 100% of performance stock units (PSUs) vested, indicating KalVista Pharmaceuticals achieved its performance data metric goals.
• The CEO's beneficial ownership remains substantial at 369,595 shares after the transactions.

Negatives

• A portion of the acquired shares (32,979 shares) was sold, although this was for tax withholding purposes and not a discretionary sale.

Industry Context

This filing details a routine insider transaction related to executive compensation, specifically the vesting of performance-based equity and a subsequent sale to cover tax obligations. It does not provide information directly related to broader industry trends, but it reflects a common practice in executive compensation within the pharmaceutical sector.

Related Party Transactions

• The acquisition and disposition of shares by Benjamin L. Palleiko, a Director and Chief Executive Officer, constitute related party transactions as they involve an insider's dealings in the company's securities.

Stakeholder Impact

• Shareholders: The vesting of PSUs due to performance metric achievement could be viewed positively as it indicates company success. The "sell to cover" transaction is a routine event and not indicative of a lack of confidence.
• Employees: The successful vesting of performance-based compensation can be a positive signal regarding the company's performance and compensation structure.

Key Dates

Recommendation

Keywords

KalVista Pharmaceuticals, KALV, SEC Form 4, Insider Trading, Beneficial Ownership, Performance Stock Units, PSU Vesting, Sell to Cover, Executive Compensation, Benjamin L. Palleiko, Director, CEO